NCT05338047: Phase 2: Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery ASCT
Updated: Feb 5
NCT05338047: Phase 2: Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant
This is a phase 2 clinical trial comparing time to neutrophil recovery after autotrasplant using generic pegfilgrastim vs brand-name pegfilgrastim.
Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Information provided by (Responsible Party)
Cesar Homero Gutierrez-Aguirre, Hospital Universitario Dr. Jose E. Gonzalez
ClinicalTrials.gov Identifier: NCT05338047
Official Title: Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilgrastim for Neutrophil Recovery After Autologous Stem Cell Transplant
First Posted: April 20, 2022
Click here to see details on ClinicalTrials.gov
Pegfilgrastim : National Cancer Institute
Drug: Pegfilgrastim
Location
Mexico
Hospital Universitario Dr. José Eleuterio González
Monterrey, Nuevo León, Mexico, 66260